Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06940856

Chloride Imbalance in Preterm Infants

In adults and children low or high blood chloride levels are linked to the risk of death. The aim of this observational study is to determine whether there is a relationship between low or high blood chloride levels and the risk of death or long-term lung problems. We will also learn the risk factors and associated conditions of high or low blood chloride levels. We will include infants born before 32 weeks of pregnancy or have a birth weight of less than 1500 grams in the study. The main question it aims to answer is:

Is there a relationship between low or high blood chloride levels in the first 4-6 weeks of life and risk of death or long-term lung problems in premature babies? We will examine the medical reports of babies who were followed up in neonatal intensive care unit over the past 5 years.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Chloride balance usually parallels that of sodium, and it is strictly correlated to the extracellular volume balance. In addition plasma chloride and bicarbonate concentrations are inversely regulated through the chloride-bicarbonate exchange pump in renal collecting ducts, independent of sodium. Consequently, plasma chloride levels are closely correlated with pH (hypochloremia/metabolic alkalosis, hyperchloremia/metabolic acidosis).

In adults, dyschloremia is associated with mortality, acute kidney injury, and prolonged hospital stay. Hyperchloremia is often associated with severe sepsis. It has been shown that resuscitation with high-chloride fluids (eg: saline solution) instead of balanced fluids (e.g., Ringer's lactate) increases the need for inotropes in critically ill adults. Similarly, hyperchloremia in septic pediatric patients is linked to acute renal injury requiring dialysis, increased inotropic support, and mortality. In 1979, infants fed with chloride-deficient formula were reported to develop impaired head growth and neurologic sequelae.

Although serum chloride is routinely measured in neonatal intensive care units, its clinical significance is often overlooked. For this reason unlike sodium, literature on chloride metabolism in preterm infants is exceedingly limited.

Advancements in perinatal care over the past 50 years have significantly improved survival rates in preterm infants. However, a large proportion of very preterm infants who survive the neonatal period develop bronchopulmonary dysplasia (BPD). BPD, a chronic lung disease, manifests clinically through persistent respiratory support and/or oxygen dependency. Despite efforts to optimize neonatal care -such as controlled oxygen usage, non-invasive ventilation, volume-guarantee techniques, high-frequency ventilation, and caffeine therapy- BPD remains the most common complication among preterm infants and is associated with increased morbidity and mortality.

It has been suggested that extracellular volume expansion (edema) plays a role in the pathophysiology of BPD. Perlman et al.'s 1986 study demonstrated that infants who died from BPD exhibited hypochloremia, metabolic alkalosis, and complications like inadequate head growth, more frequently than those who survived. These findings highlight the critical importance of chloride imbalance in neonates, similar to findings in adult and pediatric populations.

This study aims to investigate the relationship between chloride balance and two major outcomes-mortality and the development of BPD-in preterm infants. Infants <32 weeks postmentruel age (PMA) or weighing less than 1500 grams will be enrolled in the study. We also plan to explore the relationship of dyschloremia with other outcomes of prematurity (eg: patent ductus arteriosus, ventilator dependency, retinopathy of prematurity (ROP), necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia, hospital stay. Lastly we plan to explore the risk factors and clinical/laboratory conditions that are associated with chloride level abnormalities.

If this study yields findings that underscore the clinical significance of chloride levels in preterm infants, similar to adults and children, then close monitoring of chloride balance and appropriate interventions could potentially reduce mortality and BPD incidence in preterm infants. Conversely, if results indicate that chloride balance lacks clinical significance in preterm infants, this will also contribute valuable information to the current literature.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants born <32 weeks PMA or <1500 grams
  • Infants admitted to NICU within the first 24 hours

Exclusion criteria

  • Infants with major congenital anomalies
  • Infants with chromosomal anomalies
  • Infants who have undergone enterostomy operation
  • Infants admitted to NICU after the first 24 hours

Treatment and study plan

Incomplete response

Other

Infants died before 36 weeks PMA, infants diagnosed to have BPD at 36 weeks PMA and infants developed major complications before 36 weeks PMA:

  • >Stage 2 necrotizing enterocolitis according to Bell classification
  • Hemodynamically significant patent ductus arteriosus
  • >Grade 2 intraventricular hemorrhage,
  • Retinopathy of prematurity, ICROP classification stage >2
  • >Stage 2 cystic periventricular leukomalacia
  • Ventricular dilatation/hydrocephalus requiring intervention

Complete response

Other

Infants discharged before 36 weeks PMA and infants who reached 36 weeks PMA without BPD and major complications:

  • >Stage 2 necrotizing enterocolitis according to Bell classification
  • Hemodynamically significant patent ductus arteriosus
  • >Grade 2 intraventricular hemorrhage,
  • Retinopathy of prematurity, ICROP classification stage >2
  • >Stage 2 cystic periventricular leukomalacia
  • Ventricular dilatation/hydrocephalus requiring intervention

Bad response

Other

Infants died before 36 weeks PMA and infants diagnosed to have BPD at 36 weeks PMA

Primary outcomes

  1. BPD

    Time frame: From enrollment to the end of 36 weeks PMA

    BPD at 36 weeks PMA

Secondary outcomes

  1. Mortality

    Time frame: From enrollment to the end of 36 weeks PMA

    Mortality within 36 weeks PMA

Other outcomes

  1. NEC

    Time frame: From enrollment to the end of 36 weeks PMA

    >Stage 2 necrotizing enterocolitis according to Bell classification within 36 weeks PMA

  2. PDA

    Time frame: From enrollment to the end of 36 weeks PMA

    Hemodynamically significant patent ductus arteriosus within 36 weeks PMA

  3. IVH

    Time frame: From enrollment to the end of 36 weeks PMA

    >Grade 2 intraventricular hemorrhage within 36 weeks PMA

  4. ROP

    Time frame: From enrollment to the end of 36 weeks PMA

    Retinopathy of prematurity, ICROP classification stage >2 at 36 weeks PMA

  5. PVL

    Time frame: From enrollment to the end of 36 weeks PMA

    >Stage 2 cystic periventricular leukomalacia at 36 weeks PMA

  6. Hydrocephalus

    Time frame: From enrollment to the end of 36 weeks PMA

    Ventricular dilatation/hydrocephalus requiring intervention at 36 weeks PMA

Study contacts

Contact information is provided by the study sponsor or research team.

Murat Köstü

CONTACT

[email protected]

+905323932616

Sponsors and collaborators

Lead sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Other

Registry information

Official study title

The Impact of Chloride Imbalance on BPD Development and Mortality in Preterm Infants

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 23, 2025
Registry last updated
Apr 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.